Cardiovascular risk profile of patients with peripheral arterial occlusive disease during nilotinib therapy

[Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France].

Bernard Bégaud, J C Evreux, J Jouglard et al. · PubMed · 1985 · 842 citations

Medicine, Pharmacology, Pharmacovigilance +3

Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets

Uwe Rix, Oliver Hantschel, Gerhard Dürnberger et al. · Blood · 2007 · 663 citations · Full text

Life Sciences, Medicinal Chemistry, Pharmacology +17

Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML

Karl J. Aichberger, Susanne Herndlhofer, G. Schernthaner et al. · American Journal of Hematology · 2011 · 300 citations

Medicine, Hematology, Pharmacology +13

Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors

Peter Valent, Emir Hadzijusufovic, G. Schernthaner et al. · Blood · 2014 · 281 citations · Full text

Medicine, Hematology, Pharmacology +11

Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib

T D Kim, Delphine Réa, Michaela Schwarz et al. · Leukemia · 2013 · 233 citations

Medicine, Hematology, Pharmacotherapy +7